Compass Therapeutics Inc. (CMPX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Compass Therapeutics Inc.

    NASDAQ: CMPX · Real-Time Price · USD
    3.44
    0.07 (2.08%)
    At close: Sep 05, 2025, 3:59 PM
    3.46
    0.58%
    After-hours: Sep 05, 2025, 05:26 PM EDT

    Compass Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 850K n/a n/a n/a
    Cost of Revenue
    		 n/a 1.89M 1.9M 1.62M
    Gross Profit
    		 850K -1.89M -1.9M -1.62M
    Operating Income
    		 -56.63M -50.36M -41.66M -81.88M
    Interest Income
    		 7.3M n/a 2.36M 29K
    Pretax Income
    		 -49.38M -42.49M -39.23M -82.18M
    Net Income
    		 -49.38M -42.49M -36.8M -82.55M
    Selling & General & Admin
    		 15.13M 11.05M 11.66M 10.93M
    Research & Development
    		 42.34M 37.42M 30M 20.34M
    Other Expenses
    		 n/a n/a n/a 50.62M
    Operating Expenses
    		 57.48M 48.47M 41.66M 31.26M
    Interest Expense
    		 n/a n/a 2.36M 370K
    Selling & Marketing Expenses
    		 n/a 11.04M n/a n/a
    Cost & Expenses
    		 57.48M 50.36M 41.66M 31.26M
    Income Tax Expense
    		 n/a n/a -2.43M 370K
    Shares Outstanding (Basic)
    		 137.11M 127.03M 105.19M 62.87M
    Shares Outstanding (Diluted)
    		 137.11M 127.03M 105.19M 62.87M
    EPS (Basic)
    		 -0.36 -0.33 -0.35 -1.31
    EPS (Diluted)
    		 -0.36 -0.33 -0.35 -1.31
    EBITDA
    		 -54.87M -48.47M -37.39M -29.61M
    EBIT
    		 -56.63M -50.36M n/a n/a
    Depreciation & Amortization
    		 1.75M 1.89M 1.9M 1.62M

    Add to Watchlist